LLY News Alert Eli Lilly and Company (LLY) 70.16 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Eli Lilly and Company (LLY) 70.16 $LLY

Eli Lilly Set to Possibly Rebound After Yesterday's Selloff of 2.35%
Comtex SmarTrend(R) - Tue Dec 23, 4:06PM CST
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $69.01 to a high of $71.73. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $70.25 on volume of 4.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 70.16 (+0.42)

SmarTrend Watching for Potential Rebound in Shares of Eli Lilly After 2.35% Loss
Comtex SmarTrend(R) - Tue Dec 23, 4:05PM CST
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $69.01 to a high of $71.73. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $70.25 on volume of 4.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 70.16 (+0.42)

$72 Billion Pharma Company Gives Away Miracle Drug
Stephen Petranek - Daily Reckoning - Tue Dec 23, 11:13AM CST
This post $72 Billion Pharma Company Gives Away Miracle Drug appeared first on Daily Reckoning . Former editor-in-chief of Discover magazine Stephen Petranek has his eye on a special type of pharmaceutical company that has seen its stock price...
LLY: 70.16 (+0.42)

Eli Lilly-Adocia Strike Deal to Develop Ultra-Rapid Insulin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 1:50PM CST
Eli Lilly and Company (LLY) and Adocia entered into a licensing agreement to develop an ultra-rapid insulin, BioChaperone Lispro, for type I and type II diabetes.
BIIB: 340.89 (+5.13), NVO: 43.80 (+1.08), LLY: 70.16 (+0.42), MNKD: 5.68 (+0.18)

Eli Lilly to sell heartworm line for Novartis deal approval
AP - Mon Dec 22, 1:13PM CST
NEW YORK (AP) — Eli Lilly will sell its heartworm treatment for dogs to garner U.S. approval for its $5.4 billion acquisition of the animal health division belonging to Norvartis.
LLY: 70.16 (+0.42)

Lilly jettisons Sentinel line as a condition for clearance of Novartis deal
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:32AM CST

LLY: 70.16 (+0.42), NVS: 93.91 (+0.66)

Lilly Announces Diabetes Research Partnership with University of Surrey
PR Newswire Europe - Mon Dec 22, 9:19AM CST
- The five-year collaboration with the UK public research university will focus on health outcomes for people with type 2 diabetes
LLY: 70.16 (+0.42)

Radius Health osteoporosis drug candidate successful in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 7:23AM CST

RDUS: 37.17 (+0.11), LLY: 70.16 (+0.42)

Drug Giants Face $65 Billion in Lost Sales as Insurers Attack Patents
Bruce Japsen, The Motley Fool - Motley Fool - Sun Dec 21, 8:01AM CST
By 2019, pharmaceutical companies face a major loss of $65 billion in sales due to patent expirations largely from brand name central nervous system drugs that are opening up to competition from cheaper generic copies. A new report from...
ESRX: 85.48 (-0.40), AZN: 70.44 (+0.26), LLY: 70.16 (+0.42)

Zoetis: Betting The Proverbial Farm?
Marshall Hargrave - at Seeking Alpha - Sat Dec 20, 7:15AM CST

ZTS: 43.84 (+0.87), ABT: 45.70 (-0.02), MRK: 57.46 (+0.25), LLY: 70.16 (+0.42), NVS: 93.91 (+0.66)

7 Stocks Providing Their Shareholders A Growing Income With Higher Cash Dividends
Dividends4Life - at Seeking Alpha - Fri Dec 19, 9:11PM CST

MMM: 166.96 (+0.09), ABT: 45.70 (-0.02), GE: 25.83 (-0.05), PFE: 31.42 (-0.03), LLY: 70.16 (+0.42), O: 49.42 (+0.33), BA: 131.24 (+1.21)

Roche Drugs For Alzheimer's, Breast Cancer Disappoint
at Investor's Business Daily - Fri Dec 19, 10:31AM CST
Big Swiss pharma Roche (RHHBY) halted development of its Alzheimer's disease drug and reported mediocre results from a clinical trial of breast-cancer drug Kadcyla Friday, sending the stock down more than 6% in early trading on the stock market...
BIIB: 340.89 (+5.13), IMGN: 5.90 (+0.13), LLY: 70.16 (+0.42)

Lilly signs development deal for ultra-rapid insulin
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 9:50AM CST

LLY: 70.16 (+0.42)

Lilly to co-develop ultra-rapid insulin BioChaperone Lispro in partnership with Adocia
M2 - Fri Dec 19, 7:09AM CST
Healthcare company Eli Lilly and Company (NYSE:LLY) and Adocia (Euronext Paris:FR0011184241) jointly disclosed on Thursday a worldwide licensing collaboration to develop an ultra-rapid insulin, called BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes.
LLY: 70.16 (+0.42)

Eli Lilly reaches insulin development deal with Adocia
AP - Fri Dec 19, 6:16AM CST
INDIANAPOLIS (AP) — Eli Lilly and Co. could pay more than $570 million to French pharmaceutical company Adocia under an agreement to develop a fast-acting insulin that is in the early stages of clinical testing.
LLY: 70.16 (+0.42)

Diabetic Neuropathic Pain - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/qm4xdv/diabetic) has announced the addition of the "Diabetic Neuropathic Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca - Eli Lilly and Company - BioDelivery Sciences - Daiichi Sankyo - Acorda Therapeutics - Astellas Pharma - Glenmark Pharmaceuticals - KunWha Pharmaceutical - Mertiva - Grunenthal - Kyorin Pharmaceutical - Bial - Lohocla Research - Relmada Therapeutics - Sphaera Pharma - Immune Pharmaceuticals - AbbVie - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/qm4xdv/diabetic
IMNP: 1.89 (+0.02), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), ACOR: 39.14 (+0.74)

Hypercholesterolemia - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/5snkwx/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Amgen - Eli Lilly and Company - Merck & Co - Pfizer - Santaris Pharma - SoluBest - Alnylam Pharmaceuticals - Regeneron Pharmaceuticals - CrystalGenomics - Catabasis Pharmaceuticals - Planet Biotechnology - Zhejiang Hisun Pharmaceutical - Esperion Therapeutics - Progenra - Serometrix - Hanmi Pharmaceuticals - AtheroNova. - Immune Response BioPharma - Agilvax - Michigan Life Therapeutics - LondonPharma - Dybly For more information visit http://www.researchandmarkets.com/research/5s...lesterolem
JNJ: 104.59 (+0.31), ESPR: 35.97 (-0.08), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), REGN: 400.12 (+6.07)

Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology
PR Newswire - Fri Dec 19, 12:30AM CST
Eli Lilly and Company (NYSE: LLY) and Adocia (Euronext Paris: FR0011184241 - ADOC) today announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. BioChaperone Lispro relies on Adocia's proprietary BioChaperone® technology and is currently in Phase Ib studies.
LLY: 70.16 (+0.42)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 107

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 54

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 118

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 78

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 58

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading

Top 5 Most Recently Viewed Articles

Lido Staked Ether Experiences Significant Price Fluctuations

Updated Category News Views 50

The Recent Surge in Lido Staked Ether Lido Staked Ether has recently recorded a notable price increase of 3.0% in just the last 24 hours, now trading at $2,344.75. This rise seems to go against its trend over the past week, during which time the asset experienced a slight decline of 1.0%, falling from $2,333.90. The cryptocurrency has impressive highs, having reached an...

Continue Reading
Stella Artois Showcases Friendship with Super Bowl Ad Featuring Icons

Updated Category News Views 665

Stella Artois Presents an Iconic Super Bowl LIX Ad This year, Stella Artois crafts a memorable advertisement for Super Bowl LIX, showcasing the significance of connection through everyday moments. The campaign, titled 'For Moments Worth More,' aims to highlight how the simple pleasures in life can be elevated with the right company and a refreshing Stella Artois lager....

Continue Reading
Glucotrack Appoints New VP to Bolster Regulatory Strategy

Updated Category News Views 229

Glucotrack Welcomes Ted Williams as VP of Regulatory Affairs Glucotrack, Inc. is proud to announce the addition of Ted Williams as the new Vice President of Regulatory Affairs. This strategic move marks a significant step for the company as it continues to innovate and develop solutions for individuals managing diabetes. With nearly 25 years in the industry, Williams...

Continue Reading
Landstar System's Special Dividend Announcement for Shareholders

Updated Category News Views 156

Landstar System, Inc. Declares Special Cash Dividend Recently, Landstar System, Inc. (NASDAQ: LSTR) made headlines with an exciting announcement: a special one-time cash dividend of $2.00 per share. This decision, declared by the Board of Directors on a recent date, reflects the company's robust financial health and commitment to returning value to its shareholders....

Continue Reading
Market Insights: Economic Indicators and Trends to Watch

Updated Category News Views 276

Key Economic Indicators to Watch As we navigate through the current trading landscape, several economic indicators and events are set to shape the market narrative. Understanding these factors is crucial for informed trading decisions. Upcoming Economic Releases Starting the week, we have some pivotal economic releases lined up: Monday's Highlights The week begins with...

Continue Reading